Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder (Triheptanoin)

• ClinicalTrials.gov Identifier: NCT01379625
• Recruitment Status: Completed
• First Posted: June 23, 2011
• Results First Posted: March 23, 2017
• Last Update Posted: March 23, 2017
• Sponsor: Oregon Health and Science University
• Collaborator: University of Pittsburgh
• Information provided by (Responsible Party): Melanie B Gillingham, Oregon Health and Science University

Tracking Information

• First Submitted Date: June 21, 2011
• First Posted Date: June 23, 2011
• Results First Submitted Date: July 12, 2016
• Results First Posted Date: March 23, 2017
• Last Update Posted Date: March 23, 2017
• Study Start Date: September 2011
• Actual Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: March 21, 2017)

• Energy Expenditure [ Time Frame: change from baseline after 4 months of treatment ]
  Total energy expenditure will be measured by doubly labeled water and resting energy expenditure will be measured by indirect calorimetry at baseline and again after 4 months of either MCT or trihpetanoin treatment.
• Ejection Fraction [ Time Frame: 4 months ]
  Change in resting ejection fraction over 4 month treatment period

Original Primary Outcome Measures (submitted: June 22, 2011)

Energy Expenditure [ Time Frame: change from baseline after 4 months of treatment ]

Total energy expenditure will be measured by doubly labled water and resting energy expenditure will be measured by indirect calorimetry at baseline and again after 4 months of either MCT or trihpetanoin treatment.

Current Secondary Outcome Measures (submitted: March 21, 2017)

Exercise Heart Rate [ Time Frame: change from baseline to 4 months of treatment ]

Subjects will complete a submaximal treadmill exercise study at baseline. Exercise heart heart, ventilation and perceived exertion will be measured. Subjects will be randomized to MCT or triheptanoin supplementation for 4 months. At the end of treatment, the exercise test will be repeated keeping work performed constant. Change in exercise heart rate, ventilation and exertion will be compared between groups.

Original Secondary Outcome Measures (submitted: June 22, 2011)

Exercise heart rate [ Time Frame: change from baseline to 4 months of treatment ]

Subjects will complete a submaximal treadmill exercise study at baseline. Exercise heart heart, ventilation and percieved exertion will be measured. Subjects will be randomized to MCT or triheptanoin supplementation for 4 months. At the end of treatment, the exercise test will be repeated keeping work performed constant. Change in exercise heart rate, ventilation and exercition will be compared between groups.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder
• Official Title: Phase 2 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders
• Brief Summary: Humans eat long-chain fat in their diet and use it for energy during exercise and during periods of fasting. Patients with long-chain fatty acid oxidation disorders cannot use dietary fat for energy. They sometimes develop muscle breakdown, and severe pain with exercise or illness. They can also develop a heart that does not function properly. These patients are tired and expend less energy than people who do not have a long-chain fatty acid oxidation disorder. However, they can use a supplement oil called medium chain triglyceride or MCT. This study will determine if a new experimental oil called Triheptanoin can decrease the muscle pain and increase the heart function and the amount of energy in patients with long-chain fatty acid oxidation disorders. Funding source - FDA's OOPD

Detailed Description

Recruitment: Patients with a long-chain fatty acid oxidation disorder will be recruited through our clinic, past research participants, a patient support website, and recruitment letters mailed to physicians around the US. We will enroll 16 subjects at OHSU and 16 subjects at the University of Pittsburgh, age 7 to 40, with a disorder in fatty acid oxidation.

Procedures: Subjects will be admitted to the clinical research center for 4 days. They will collect all their urine for 24 hours. Heart function will be measured using ultrasound an electrocardiogram (ECG). The motion of the heart will be measured by magnetic resonance imaging (MRI). For this test, the patient lies in the magnetic field of the MRI machine in the Advanced Imaging Resource Center (AIRC) for about 45 minutes. The amount of muscle and fat in the whole body and inside the liver and muscle will be measured by MRS and by dual X-ray absorptiometry (DEXA). Subjects will walk on a treadmill for about 45 minutes. The amount of Calories they use, their heart rate, and if they burn fat or carbohydrates will be measured. Blood samples will be collected before and after exercise. A meal test will be used to determine how much fat they burn. The subjects will drink a liquid breakfast with a stable isotope labeled fat in the breakfast. Breath and blood samples will be collected before and after the meal. The amount Calories burned by each subject will be measured when they are at rest on a bed by indirect calorimetry. The amount of Calories burned by subjects when they are doing their routine daily activities will be measured at home by doubly labeled water. All of these tests will be done at baseline. Then, subjects will be randomly assigned to consume MCT (current standard of care) or triheptanoin at 20% of their estimated Calorie needs for 4 months. The subject and/or the parent will be taught how to use the supplement oil in their diet for cooking and baking. The subject will be sent home and the oil will be shipped to their home. The study coordinator will call the subject or subject's guardian each week to monitor the subject's diet, potential side effects and assist with diet planning. At the end of 4 months, all of the baseline tests will be repeated.

Triheptanoin is experimental oil. It is a clear, odorless oil that can be mixed with foods and used in cooking. Almost all oils are made from even chains of carbon molecules. Triheptanoin is different because the carbon chains are odd in number. The co-investigator of this study at the University of Pittsburgh, Dr. Jerry Vockely, holds an IND for the prescription, and use of triheptanoin in humans (IND 106011).

Data Analysis: The change in exercise ability, heart function, Calories used and body fat after 4 months will be compared between subjects randomized to MCT versus triheptanoin.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment

Condition

• Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency
• Carnitine Palmitoyltransferase 2 (CPT2) Deficiency
• Mitochondrial Trifunctional Protein (TFP) Deficiency
• Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) Deficiency

Intervention

Drug: Triheptanoin

Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone

Other Names:

• IND 113386
• C7

Study Arms

• Active Comparator: Medium Chain Triglyceride (MCT)
  Subjects randomized to consume 20% of energy from MCT
  Intervention: Drug: Triheptanoin
• Experimental: Triheptanoin
  Subject randomized to consume 20% of energy from triheptanoin.
  Intervention: Drug: Triheptanoin

• Publications *: Gillingham MB, Heitner SB, Martin J, Rose S, Goldstein A, El-Gharbawy AH, Deward S, Lasarev MR, Pollaro J, DeLany JP, Burchill LJ, Goodpaster B, Shoemaker J, Matern D, Harding CO, Vockley J. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial. J Inherit Metab Dis. 2017 Nov;40(6):831-843. doi: 10.1007/s10545-017-0085-8. Epub 2017 Sep 4.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: June 22, 2011): 32
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: April 2015
• Actual Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Confirmed diagnosis of Very long-chain acylCoA dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase 2 (CPT2) Deficiency, Mitochondrial Trifunctional Protein (TFP) Deficiency, or Long-chain 3 hydroxyacylCoA dehydrogenase (LCHAD) deficiency
• > 7 years
• Ability to travel to CRC to participate
• Ability to follow protocol

Exclusion Criteria:

• Hgb < 10 g/dl
• Peripheral neuropathy that limits ability to complete treadmill studies
• Inclusion in another research study that alters macronutrient intake
• Pregnant females
• history of myocardial infarction or cardiovascular disease

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 7 Years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT01379625
• Other Study ID Numbers: FD003895
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Melanie B Gillingham, Oregon Health and Science University
• Original Responsible Party: Melanie B Gillingham, PhD, RD Assistant Professor, Oregon Health & Science University
• Current Study Sponsor: Oregon Health and Science University
• Original Study Sponsor: Same as current
• Collaborators: University of Pittsburgh

Investigators

• Principal Investigator: Melanie B Gillingham, PhD; Oregon Health and Science University

• PRS Account: Oregon Health and Science University
• Verification Date: March 2017